These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37222881)

  • 1. Open-source automated insulin delivery systems (OS-AIDs) in a pediatric population with type 1 diabetes in a real-life setting: the AWeSoMe study group experience.
    Nir J; Rachmiel M; Fraser A; Lebenthal Y; Brener A; Pinhas-Hamiel O; Haim A; Stern E; Levek N; Ben-Ari T; Landau Z
    Endocrine; 2023 Aug; 81(2):262-269. PubMed ID: 37222881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous subcutaneous insulin infusion versus multiple daily injections in children and young people at diagnosis of type 1 diabetes: the SCIPI RCT.
    Blair J; McKay A; Ridyard C; Thornborough K; Bedson E; Peak M; Didi M; Annan F; Gregory JW; Hughes D; Gamble C
    Health Technol Assess; 2018 Aug; 22(42):1-112. PubMed ID: 30109847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positive Impact of the Bionic Pancreas on Diabetes Control in Youth 6-17 Years Old with Type 1 Diabetes: A Multicenter Randomized Trial.
    Messer LH; Buckingham BA; Cogen F; Daniels M; Forlenza G; Jafri RZ; Mauras N; Muir A; Wadwa RP; White PC; Russell SJ; Damiano ER; El-Khatib FH; Ruedy KJ; Balliro CA; Li Z; Marak MC; Calhoun P; Beck RW
    Diabetes Technol Ther; 2022 Oct; 24(10):712-725. PubMed ID: 36173237
    [No Abstract]   [Full Text] [Related]  

  • 4. Use of flash glucose-sensing technology (FreeStyle Libre) in youth with type 1 diabetes: AWeSoMe study group real-life observational experience.
    Landau Z; Abiri S; Gruber N; Levy-Shraga Y; Brener A; Lebenthal Y; Barash G; Pinhas-Hamiel O; Rachmiel M
    Acta Diabetol; 2018 Dec; 55(12):1303-1310. PubMed ID: 30171412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective Analysis of the Impact of Commercialized Hybrid Closed-Loop System on Glycemic Control, Glycemic Variability, and Patient-Related Outcomes in Children and Adults: A Focus on Superiority Over Predictive Low-Glucose Suspend Technology.
    Beato-Víbora PI; Gallego-Gamero F; Lázaro-Martín L; Romero-Pérez MDM; Arroyo-Díez FJ
    Diabetes Technol Ther; 2020 Dec; 22(12):912-919. PubMed ID: 31855446
    [No Abstract]   [Full Text] [Related]  

  • 6. Real-World Use of Do-It-Yourself Artificial Pancreas Systems in Children and Adolescents With Type 1 Diabetes: Online Survey and Analysis of Self-Reported Clinical Outcomes.
    Braune K; O'Donnell S; Cleal B; Lewis D; Tappe A; Willaing I; Hauck B; Raile K
    JMIR Mhealth Uhealth; 2019 Jul; 7(7):e14087. PubMed ID: 31364599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sleep and diabetes-specific psycho-behavioral outcomes of a new automated insulin delivery system in young children with type 1 diabetes and their parents.
    Bisio A; Brown SA; McFadden R; Pajewski M; Yu PL; DeBoer M; Schoelwer MJ; Bonner HG; Wakeman CA; Cherñavvsky DR; Gonder-Frederick L
    Pediatr Diabetes; 2021 May; 22(3):495-502. PubMed ID: 33289242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methods for insulin delivery and glucose monitoring in diabetes: summary of a comparative effectiveness review.
    Golden SH; Sapir T
    J Manag Care Pharm; 2012 Aug; 18(6 Suppl):S1-17. PubMed ID: 22984955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-school and school-aged children benefit from the switch from a sensor-augmented pump to an AndroidAPS hybrid closed loop: A retrospective analysis.
    Petruzelkova L; Jiranova P; Soupal J; Kozak M; Plachy L; Neuman V; Pruhova S; Obermannova B; Kolouskova S; Sumnik Z
    Pediatr Diabetes; 2021 Jun; 22(4):594-604. PubMed ID: 33576551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of insulin degludec and insulin glargine over NPH insulin among toddlers and preschoolers with type 1 diabetes using glycemic variability and time in range.
    Elhabashy SA; Sakr EM; Salah NY
    Eur J Pediatr; 2023 Apr; 182(4):1857-1868. PubMed ID: 36800034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the Hybrid Closed-Loop System on Sleep and Quality of Life in Youth with Type 1 Diabetes and Their Parents.
    Cobry EC; Hamburger E; Jaser SS
    Diabetes Technol Ther; 2020 Nov; 22(11):794-800. PubMed ID: 32212971
    [No Abstract]   [Full Text] [Related]  

  • 12. Real-world prospective observational single-centre study: Hybrid closed loop improves HbA1c, time-in-range and quality of life for children, young people and their carers.
    Ng SM; Katkat N; Day H; Hubbard R; Quinn M; Finnigan L
    Diabet Med; 2022 Jul; 39(7):e14863. PubMed ID: 35488481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A real-world study of user characteristics, safety and efficacy of open-source closed-loop systems and Medtronic 670G.
    Jeyaventhan R; Gallen G; Choudhary P; Hussain S
    Diabetes Obes Metab; 2021 Aug; 23(8):1989-1994. PubMed ID: 33999488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing Insulin Pump Devices in Real Life: The AWeSoMe Study Group Prospective Experience.
    Rachmiel M; Levy-Shraga Y; Gruber N; Pinhas-Hamiel O; Barash G; Pivko-Levy D; Landau Z
    Diabetes Technol Ther; 2019 Mar; 21(3):138-145. PubMed ID: 30702335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Sensor-Augmented Pump Therapy with Predictive Low-Glucose Suspend Function on Glycemic Control and Patient Satisfaction in Adults and Children with Type 1 Diabetes.
    Beato-Víbora PI; Quirós-López C; Lázaro-Martín L; Martín-Frías M; Barrio-Castellanos R; Gil-Poch E; Arroyo-Díez FJ; Giménez-Álvarez M
    Diabetes Technol Ther; 2018 Nov; 20(11):738-743. PubMed ID: 30256132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of automated insulin delivery systems in children and adolescents with type 1 diabetes Mellitus: A systematic review and meta-analysis of randomized controlled trials.
    Michou P; Gkiourtzis N; Christoforidis A; Kotanidou EP; Galli-Tsinopoulou A
    Diabetes Res Clin Pract; 2023 May; 199():110678. PubMed ID: 37094750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Meta-Analysis of Randomized Trial Outcomes for the t:slim X2 Insulin Pump with Control-IQ Technology in Youth and Adults from Age 2 to 72.
    Beck RW; Kanapka LG; Breton MD; Brown SA; Wadwa RP; Buckingham BA; Kollman C; Kovatchev B
    Diabetes Technol Ther; 2023 May; 25(5):329-342. PubMed ID: 37067353
    [No Abstract]   [Full Text] [Related]  

  • 18. Extended Use of an Open-Source Automated Insulin Delivery System in Children and Adults with Type 1 Diabetes: The 24-Week Continuation Phase Following the CREATE Randomized Controlled Trial.
    Burnside MJ; Lewis DM; Crocket HR; Meier RA; Williman JA; Sanders OJ; Jefferies CA; Faherty AM; Paul RG; Lever CS; Price SKJ; Frewen CM; Jones SD; Gunn TC; Lampey C; Wheeler BJ; de Bock MI
    Diabetes Technol Ther; 2023 Apr; 25(4):250-259. PubMed ID: 36763345
    [No Abstract]   [Full Text] [Related]  

  • 19. Real-World Patient-Reported Outcomes and Glycemic Results with Initiation of Control-IQ Technology.
    Pinsker JE; Müller L; Constantin A; Leas S; Manning M; McElwee Malloy M; Singh H; Habif S
    Diabetes Technol Ther; 2021 Feb; 23(2):120-127. PubMed ID: 32846114
    [No Abstract]   [Full Text] [Related]  

  • 20. Glycemic outcomes of Advanced Hybrid Closed Loop system in children and adolescents with Type 1 Diabetes, previously treated with Multiple Daily Injections (MiniMed 780G system in T1D individuals, previously treated with MDI).
    Petrovski G; Al Khalaf F; Campbell J; Day E; Almajaly D; Hussain K; Pasha M; Umer F; Hamdan M; Khalifa A
    BMC Endocr Disord; 2022 Mar; 22(1):80. PubMed ID: 35351095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.